Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab.
Courby
Stéphane
S
Fabre
Blandine
B
Salameire
Dimitri
D
Gaulard
Philippe
P
Hincky-Vitrat
Virginie
V
Gressin
Rémy
R
Bonaz
Bruno
B
Epaulard
Olivier
O
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology*; D003424:Crohn Disease / Q000150:complications; D005260:Female; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000150:complications / Q000175:diagnosis / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000821:virology; D000069283:Rituximab; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab; D001379:Azathioprine